CTP-543 for Alopecia Areata

"The clinical trial in question, while no longer recruiting patients, was last updated on 10/28/2022. This is according to information found on clinicaltrials.gov. There are currently 93 other active studies that are enrolling patients."

"CTP-543 is a Phase 2 drug, meaning that while there is some data supporting its safety, there is no clinical evidence yet of the medication's efficacy. Our team at Power rates it as a 2 on our safety scale."

"This study is currently enrolling patients from 40 different locations, including Center for Dermatology and Plastic Surgery/CCT Research in Scottsdale, Arizona, Austin Institute for Clinical Research in Houston, Texas, and Kaiser Permanente in Oakland, California."

"This trial is looking for 300 patients with alopecia areata, between the ages of 18 and 65. Patients must also meet the following criteria: At least 50% scalp hair loss, as defined by a SALT score ≥50, at Screening and Baseline., Willing to comply with the study visits and requirements of the study protocol., Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.."

"The age group of 18 to 65 is eligible for this trial, with 10 other trials offered to those under 18 and 67 options available for seniors."

"The primary outcome of this 24-week study, as stated by the trial's sponsor, Concert Pharmaceuticals, will be measuring the Proportion of patients by dose group achieving restoration of regrowth. However, there are also secondary outcomes being assessed which include Part A, Period 1: Percentage of responders (defined as "satisfied" or "very satisfied") on the Hair Satisfaction Patient Reported Outcome (SPRO) scale which is defined as SPRO is a questionnaire answered by the patient designed to measure how satisfied alopecia areata patients are with their hair at the time of the assessment., Part A, Period 1:"